
    
      This was a phase 2a multicenter, open-label, sequential, 3-arm, combination treatment study
      of a regimen of ABT-450/r/ABT-333, and ribavirin (RBV) in hepatitis C virus (HCV) genotype
      1-infected treatment-na√Øve participants and previous non-responders to pegylated interferon
      (pegIFN)/RBV treatment.
    
  